The Cancer Support Community Delivers Groundbreaking Immunotherapy Support and Education Program to Patients …GlobeNewswire (press release)Washington, D.C., Sept. 06, 2017 (GLOBE NEWSWIRE) — The Cancer Support Community (CSC), an international nonpr… Continue reading
Labiotech.eu |
Merck to Acquire Rigontec, Expanding Cancer Immunotherapy Franchise
Genetic Engineering & Biotechnology News Merck & Co. has agreed to acquire Rigontec for up to €464 million (about $554 million), in a deal that will expand the cancer immunotherapy franchise of the Keytruda® (pembrolizumab) developer with a three-year-old Bonn University spinout whose … Merck, looking to build on cancer success, buys IO biotech RigontecFierceBiotech Merck To Buy RigontecNasdaq MSD to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-OncologyBusiness Wire (press release) |
|
Patient’s immune status associated with outcome following third-generation CAR T-cell therapy
Medical Xpress Treatment with third-generation CAR T–cell therapy led to a complete response in six of 15 patients with a CD19-positive B-cell malignancy and overall survival was associated with the patient’s immune status, according to data from a phase I/IIa … |
|
Patient’s immune status associated with outcome following third …
Medical Xpress Treatment with third-generation CAR T–cell therapy led to a complete response in six of 15 patients with a CD19-positive B-cell malignancy and overall survival … Immune Status Tied to Outcomes in Third-Gen CAR T-Cell Therapy …Doctors Lounge |
|
Endocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage Cytokine Release …
Nasdaq “The clinical success and recent regulatory approval of the first CAR T-cell therapy has shown the efficacy of CAR T-cell technologies in hematological malignancies and the potential promise of the treatment in solid tumors as well. However, these … Poseida Therapeutics Presents Novel BCMA-Specific CAR–T Therapy at CAR-TCR SummitEconoTimes |
|
Endocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage Cytokine Release …
GlobeNewswire (press release) “The clinical success and recent regulatory approval of the first CAR T-cell therapy has shown the efficacy of CAR T-cell technologies in hematological malignancies and the potential promise of the treatment in solid tumors as well. However, these … Poseida Therapeutics Presents Novel BCMA-Specific CAR–T Therapy at CAR-TCR SummitEconoTimes |
STAT |
Voyager Therapeutics gene therapy improves motor function in Parkinson’s patients
STAT gene therapy from Voyager Therapeutics (VYGR 1) delivered surgically into the brains of patients with advanced Parkinson’s disease reduced their need for standard Parkinson’s medications and improved motor function, according to results from a small, … Voyager Therapeutics posts added proof its gene therapy for Parkinson’s can workEndpoints News Voyager Therapeutics Announces Positive Results from Ongoing Phase 1b Trial of VY-AADC01 for Advanced …GlobeNewswire (press release) Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock Closed Well Above Its 50 Day Moving AverageFirst News 24 |